2 Information about secukinumab

Marketing authorisation indication

2.1 Secukinumab (Cosentyx, Novartis) has a marketing authorisation for 'the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of secukinumab is £609.39 for a 150 mg/ml prefilled syringe (excluding VAT; BNF online, accessed August 2021).

2.4 The company has a commercial arrangement. This makes secukinumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)